gnckКолопроктологияKoloproktologia2073-75562686-7303Russian Association of Coloproctology10.33878/2073-7556-2024-23-2-173-183gnck-1908Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWАктуальна ли терапия инфликсимабом в настоящее время у пациентов с воспалительными заболеваниями кишечника? (обзор литературы)Is infliximab therapy currently relevant in patients with inflammatory bowel diseases? (review)https://orcid.org/0000-0002-8803-7566АлександровТ. Л.AlexandrovT. L.

Александров Тимофей Леонидович — младший научный сотрудник отдела по изучению функциональных и воспалительных заболеваний кишечника

 +7 917 518 82 94

ул. Саляма Адиля, д. 2, г. Москва, 123423, Россия 

 +7 917 518 82 94 

Salyama Adilya str., 2, Moscow, Russia

aleksandrov_tl@gnck.ruhttps://orcid.org/0000-0003-1697-4670ВыковаБ. А.VykovaB. A.

Выкова Бэлла Александровна — к.м.н., заведующая гастроэнтерологическим отделением 

ул. Саляма Адиля, д. 2, г. Москва, 123423, Россия

Salyama Adilya st., 2, Moscow, 123423, Russia

ФГБУ "НМИЦ колопроктологии имени А.Н.Рыжих" Минздрава РоссииРоссияRyzhikh National Medical Research Center of ColoproctologyRussian FederationФГБУ «НМИЦ колопроктологии имени А.Н. Рыжих» Минздрава РоссииRussian FederationRyzhikh National Medical Research Center of ColoproctologyRussian Federation202421062024232173183Copyright © Александров Т.Л., Выкова Б.А., 20242024Александров Т.Л., Выкова Б.А.Alexandrov T.L., Vykova B.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.ruproctology.com/jour/article/view/1908

ВВЕДЕНИЕ: в настоящее время в лечении среднетяжёлых форм воспалительных заболеваний кишечника (ВЗК) активно используются генно-инженерные препараты (ГИБП) и таргетные иммуносупрессоры (ТИС). Несмотря на значительное улучшение исходов заболеваний, улучшения качества жизни пациентов и снижение хирургической активности, в долгосрочной перспективе полноценной клинико-инструментальной ремиссии нередко достигнуть не удается, или с течением времени ответ теряется.ЦЕЛЬ: систематизация данных об эффективности и безопасности терапии ВЗК инфликсимабом, а также методам ранней и поздней оценки эффективности; показаниям, видам и особенностям оптимизации терапии.ВЫВОДЫ: несмотря на появление сравнительно большого количества новых ГИБП и ТИС, остается проблема неэффективности или потери ответа. На наш взгляд, решением этой проблемы может быть персонификация назначения и режимов терапии ГИБП. В настоящее время есть немало исследований, посвященных как клиническим, так и лабораторным маркерам, имеющим прогностическое значение в ведении пациентов с ВЗК при терапии инфликсимабом. Однако эти исследования не валидированы для российской популяции пациентов. Требуется проведение многоцентровых исследований на российской популяции пациентов.

INTRODUCTION: genetically engineered biological drugs (GIBD) used in the treatment of moderate to severe inflammatory bowel diseases (IBD) currently. Despite a significant improvement in disease outcomes, improvement in the quality of life of patients and a decrease in surgical activity, in the long term, it is often not possible to achieve full-fledged clinical and instrumental remission or the loose of response over time.OBJECTIVE: to systematize data on the efficacy and safety of IBD infliximab therapy, as well as methods of early and late efficacy assessment; indications, types and features of therapy optimization.CONCLUSIONS: despite the appearance of a relatively large number of new GIBD and TIS, the problem of inefficiency or loss of response remains. In our opinion, the solution to this problem may be the personification of the appointment and treatment regimens of GIBP. Currently, there are many studies devoted to both clinical and laboratory markers of prognostic importance in the management of patients with IBD during infliximab therapy. However, these studies are not localized for the Russian patient population. Multicenter studies on the Russian patient population are required.

воспалительные заболевания кишечникаВЗКязвенный колитЯКболезнь КронаБКгенно-инженерная биологическая терапияГИБПinflammatory bowel diseasesIBDulcerative colitisUCCrohn’s diseaseCDgenetically engineered biological therapyGIBPReferencesБудзинская А.А., Белоусова Е.А., Вакурова Е.С., и соавт. Эндосонографические изменения поджелудочной железы у больных с воспалительными заболеваниями кишечника и хроническим панкреатитом. Экспериментальная и клиническая гастроэнтерология. 2023;(3):53–60. doi: 10.31146/1682-8658-ecg-211-3-53-60Budzinskaya A.A., Belousova E.A., Vakurova E.S., et al. Endosonographic changes of the pancreas in patients with inflammatory bowel diseases and chronic pancreatitis. Experimental and clinical gastroenterology. 2023;(3):53–60. (in Russ.). doi: 10.31146/1682-8658-ecg-211-3-53-60Darie AM, Sinopoulou V, Ajay V, et al. BSG 2024 IBD guidelines protocol (standard operating procedures). BMJ Open Gastroenterol. 2023 Feb;10(1):e001067. doi: 10.1136/bmjgast-2022-001067Darie AM, Sinopoulou V, Ajay V, et al. BSG 2024 IBD guidelines protocol (standard operating procedures). BMJ Open Gastroenterol. 2023 Feb;10(1):e001067. doi: 10.1136/bmjgast-2022-001067Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344(8930):1105–10. doi: 10.1016/s0140-6736(94)90628-9Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344(8930):1105–10. doi: 10.1016/s0140-6736(94)90628-9Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med. 1997;337(15):1029–35Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med. 1997;337(15):1029–35Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9. doi: 10.1016/S0140-6736(02)08512-4Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9. doi: 10.1016/S0140-6736(02)08512-4Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76. doi: 10.1056/NEJMoa050516Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76. doi: 10.1056/NEJMoa050516Kim NH, Lee JH, Hong SN, et al. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J Gastroenterol Hepatol. 2019;34(9):1523–1532. doi: 10.1111/jgh.14645Kim NH, Lee JH, Hong SN, et al. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J Gastroenterol Hepatol. 2019;34(9):1523–1532. doi: 10.1111/jgh.14645Nencini F, Vultaggio A, Pratesi S, et al. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. J Allergy ClinImmunol Pract. 2018;6(6):2065–2072.e2. doi: 10.1016/j.jaip.2018.04.007Nencini F, Vultaggio A, Pratesi S, et al. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. J Allergy ClinImmunol Pract. 2018;6(6):2065–2072.e2. doi: 10.1016/j.jaip.2018.04.007Нуриахметова Т.Ю., Валеева И.Х., Шевнина Я.О., и соавт. Эффективность ингибиторов фактора некроза опухоли α в лечении различных иммуновоспалительных заболеваний: фокус на иммуногенность. Современная ревматология. 2023;17(4):35–41. doi: 10.14412/1996-7012-2023-4-35-41Nuriakhmetova T.Yu., Valeeva I.H., Shevnina Ya.O., et al. The effectiveness of tumor necrosis factor α inhibitors in the treatment of various immuno-inflammatory diseases: focus on immunogenicity. Modern rheumatology. 2023;17(4):35–41. (in Russ.). doi: 10.14412/1996-7012-2023-4-35-41Reinisch W, Gecse K, Halfvarson J, et al. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease. Inflamm Bowel Dis. 2021;27(1):106–122. doi: 10.1093/ibd/izaa078Reinisch W, Gecse K, Halfvarson J, et al. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease. Inflamm Bowel Dis. 2021;27(1):106–122. doi: 10.1093/ibd/izaa078Tsui JJ, Huynh HQ. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn’s disease? Ann Gastroenterol. 2018;31(4):413–424. doi: 10.20524/aog.2018.0253Tsui JJ, Huynh HQ. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn’s disease? Ann Gastroenterol. 2018;31(4):413–424. doi: 10.20524/aog.2018.0253Papamichael K, Vajravelu RK, Osterman MT, et al. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(3):761–767. doi: 10.1007/s10620-018-4917-7Papamichael K, Vajravelu RK, Osterman MT, et al. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(3):761–767. doi: 10.1007/s10620-018-4917-7Feng T, Chen B, Ungar B, et al. Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn’s Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment. Inflamm Bowel Dis. 2019;25(11):1813–1821. doi: 10.1093/ibd/izz061Feng T, Chen B, Ungar B, et al. Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn’s Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment. Inflamm Bowel Dis. 2019;25(11):1813–1821. doi: 10.1093/ibd/izz061Papamichael K, Vande Casteele N, Jeyarajah J, et al. Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn’s Disease: An ACCENT-II Post Hoc Analysis. Am J Gastroenterol. 2021;116(5):1007–1014. doi: 10.14309/ajg.0000000000001111Papamichael K, Vande Casteele N, Jeyarajah J, et al. Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn’s Disease: An ACCENT-II Post Hoc Analysis. Am J Gastroenterol. 2021;116(5):1007–1014. doi: 10.14309/ajg.0000000000001111Koga A, Matsui T, Takatsu N, et al. Trough level of infliximab is useful for assessing mucosal healing in Crohn’s disease: a prospective cohort study. Intest Res. 2018;16(2):223–232. doi: 10.5217/ir.2018.16.2.223Koga A, Matsui T, Takatsu N, et al. Trough level of infliximab is useful for assessing mucosal healing in Crohn’s disease: a prospective cohort study. Intest Res. 2018;16(2):223–232. doi: 10.5217/ir.2018.16.2.223Blanchard F, Wang Y, Kinzie E, et al. Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms. J Biol Chem. 2001;276(50):47038–45. doi: 10.1074/jbc.M107971200Blanchard F, Wang Y, Kinzie E, et al. Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms. J Biol Chem. 2001;276(50):47038–45. doi: 10.1074/jbc.M107971200Кручинина М.В., Светлова И.О., Осипенко М.Ф., и соавт. Значимость уровней сывороточных маркеров для оценки статуса и прогноза больных с воспалительными заболеваниями кишечника. Экспериментальная и клиническая гастроэнтерология. 2023;212(4):121–132. doi: 10.31146/1682-8658-ecg-212-4-121-132Kruchinina M.V., Svetlova I.O., Osipenko M.F., et al. The significance of serum marker levels for assessing the status and prognosis of patients with inflammatory bowel diseases. Experimental and clinical gastroenterology. 2023;212(4):121–132 (in Russ.). doi: 10.31146/1682-8658-ecg-212-4-121-132Bertani L, Fornai M, Fornili M, et al. Serum oncostatin M at baseline predicts mucosal healing in Crohn’s disease patients treated with infliximab. Aliment Pharmacol Ther. 2020;52(2):284–291. doi: 10.1111/apt.15870Bertani L, Fornai M, Fornili M, et al. Serum oncostatin M at baseline predicts mucosal healing in Crohn’s disease patients treated with infliximab. Aliment Pharmacol Ther. 2020;52(2):284–291. doi: 10.1111/apt.15870Verstockt B, Verstockt S, Dehairs J, et al. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. E Bio Medicine. 2019;40:733–742. doi: 10.1016/j.ebiom.2019.01.027Verstockt B, Verstockt S, Dehairs J, et al. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. E Bio Medicine. 2019;40:733–742. doi: 10.1016/j.ebiom.2019.01.027Andreou NP, Legaki E, Dovrolis N, et al. B-cell activating factor (BAFF) expression is associated with Crohn’s disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment. Dig Liver Dis. 2021 May;53(5):574–580. doi: 10.1016/j.dld.2020.11.030Andreou NP, Legaki E, Dovrolis N, et al. B-cell activating factor (BAFF) expression is associated with Crohn’s disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment. Dig Liver Dis. 2021 May;53(5):574–580. doi: 10.1016/j.dld.2020.11.030Jahnsen J, Kaasen Jørgensen K. Experience with Biosimilar Infliximab (Remsima®) in Norway. Dig Dis. 2017;35(1-2):83–90. doi: 10.1159/000449088.21Jahnsen J, Kaasen Jørgensen K. Experience with Biosimilar Infliximab (Remsima®) in Norway. Dig Dis. 2017;35(1-2):83–90. doi: 10.1159/000449088.21Lega S, Phan BL, Rosenthal CJ, et al. Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD. Inflamm Bowel Dis. 2019;25(1):134–141. doi: 10.1093/ibd/izy203Lega S, Phan BL, Rosenthal CJ, et al. Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD. Inflamm Bowel Dis. 2019;25(1):134–141. doi: 10.1093/ibd/izy203D’Haens G, Vermeire S, Lambrecht G, et al. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease. Gastroenterology. 2018;154(5):1343–1351.e1. doi: 10.1053/j.gastro.2018.01.004D’Haens G, Vermeire S, Lambrecht G, et al. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease. Gastroenterology. 2018;154(5):1343–1351.e1. doi: 10.1053/j.gastro.2018.01.004Papamichael K, Rakowsky S, Rivera C, et al. Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn’s Disease. Inflamm Bowel Dis. 2018;24(10):2266–2271. doi: 10.1093/ibd/izy132Papamichael K, Rakowsky S, Rivera C, et al. Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn’s Disease. Inflamm Bowel Dis. 2018;24(10):2266–2271. doi: 10.1093/ibd/izy132Fernandes SR, Bernardo S, Simões C, et al. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020;26(2):263–270. doi: 10.1093/ibd/izz131Fernandes SR, Bernardo S, Simões C, et al. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020;26(2):263–270. doi: 10.1093/ibd/izz131Fernandes SR, Serrazina J, Rodrigues IC, et al. Proactive therapeutic drug monitoring is more effective than conventional management in inducing fecal calprotectin remission in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2021;33(12):1539–1546. doi: 10.1097/MEG.0000000000002111Fernandes SR, Serrazina J, Rodrigues IC, et al. Proactive therapeutic drug monitoring is more effective than conventional management in inducing fecal calprotectin remission in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2021;33(12):1539–1546. doi: 10.1097/MEG.0000000000002111Ricciuto A, Dhaliwal J, Walters TD, et al. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis. J Crohns Colitis. 2018;12(11):1302–1315. doi: 10.1093/ecco-jcc/jjy109Ricciuto A, Dhaliwal J, Walters TD, et al. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis. J Crohns Colitis. 2018;12(11):1302–1315. doi: 10.1093/ecco-jcc/jjy109Papamichael K, Vajravelu RK, Vaughn BP, et al. Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2018;12(7):804–810. doi: 10.1093/ecco-jcc/jjy039Papamichael K, Vajravelu RK, Vaughn BP, et al. Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2018;12(7):804–810. doi: 10.1093/ecco-jcc/jjy039Hoseyni H, Xu Y, Zhou H. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment? J Clin Pharmacol. 2018;58(7):864–876. doi: 10.1002/jcph.1084Hoseyni H, Xu Y, Zhou H. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment? J Clin Pharmacol. 2018;58(7):864–876. doi: 10.1002/jcph.1084Laterza L, Ainora ME, Garcovich M, et al. Bowel contrastenhanced ultrasound perfusion imaging in the evaluation of Crohn’s disease patients undergoing anti-TNFα therapy. Dig Liver Dis. 2021;53(6):729–737. doi: 10.1016/j.dld.2020.08.005Laterza L, Ainora ME, Garcovich M, et al. Bowel contrastenhanced ultrasound perfusion imaging in the evaluation of Crohn’s disease patients undergoing anti-TNFα therapy. Dig Liver Dis. 2021;53(6):729–737. doi: 10.1016/j.dld.2020.08.005Targownik LE, Benchimol EI, Bernstein CN, et al. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. J Crohns Colitis. 2020;14(10):1354–1363. doi: 10.1093/ecco-jcc/jjaa050Targownik LE, Benchimol EI, Bernstein CN, et al. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. J Crohns Colitis. 2020;14(10):1354–1363. doi: 10.1093/ecco-jcc/jjaa050Targownik LE, Benchimol EI, Bernstein CN, et al. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. Clin Gastroenterol Hepatol. 2019;17(9):1788–1798.e2. doi: 10.1016/j.cgh.2018.11.003Targownik LE, Benchimol EI, Bernstein CN, et al. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. Clin Gastroenterol Hepatol. 2019;17(9):1788–1798.e2. doi: 10.1016/j.cgh.2018.11.003Mogensen DV, Brynskov J, Ainsworth MA, et al. A Role for Thiopurine Metabolites in the Synergism BetweenThiopurines and Infliximab in Inflammatory Bowel Disease. J Crohns Colitis. 2018;12(3):298–305. doi: 10.1093/ecco-jcc/jjx149Mogensen DV, Brynskov J, Ainsworth MA, et al. A Role for Thiopurine Metabolites in the Synergism BetweenThiopurines and Infliximab in Inflammatory Bowel Disease. J Crohns Colitis. 2018;12(3):298–305. doi: 10.1093/ecco-jcc/jjx149Colombel JF, Adedokun OJ, Gasink C, et al. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019;17(8):1525–1532.e1. doi: 10.1016/j.cgh.2018.09.033Colombel JF, Adedokun OJ, Gasink C, et al. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019;17(8):1525–1532.e1. doi: 10.1016/j.cgh.2018.09.033Mattoo VY, Basnayake C, Connell WR, et al. Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn’s disease. Aliment Pharmacol Ther. 2021;54(3):249–266. doi: 10.1111/apt.16479Mattoo VY, Basnayake C, Connell WR, et al. Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn’s disease. Aliment Pharmacol Ther. 2021;54(3):249–266. doi: 10.1111/apt.16479Drobne D, Kurent T, Golob S, et al. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(7):880–889. doi: 10.1111/apt.15179Drobne D, Kurent T, Golob S, et al. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(7):880–889. doi: 10.1111/apt.15179Srinivasan A, Vasudevan A, McFarlane A, et al. Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn’s Disease. J Crohns Colitis. 2018;12(3):280–288. doi: 10.1093/eccojcc/jjx144Srinivasan A, Vasudevan A, McFarlane A, et al. Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn’s Disease. J Crohns Colitis. 2018;12(3):280–288. doi: 10.1093/eccojcc/jjx144Drobne D, Kurent T, Golob S, et al. Success and safety of high infliximab trough levels in inflammatory bowel disease. Scand J Gastroenterol. 2018;53(8):940–946. doi: 10.1080/00365521.2018.1486882Drobne D, Kurent T, Golob S, et al. Success and safety of high infliximab trough levels in inflammatory bowel disease. Scand J Gastroenterol. 2018;53(8):940–946. doi: 10.1080/00365521.2018.1486882Syversen SW, Jørgensen KK, Goll GL, et al. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. JAMA. 2021;326(23):2375–2384. doi: 10.1001/jama.2021.21316Syversen SW, Jørgensen KK, Goll GL, et al. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. JAMA. 2021;326(23):2375–2384. doi: 10.1001/jama.2021.21316Barclay ML, Karim S, Helms ETJ, et al. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. Intern Med J. 2019;49(4):513–518. doi: 10.1111/imj.14064Barclay ML, Karim S, Helms ETJ, et al. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. Intern Med J. 2019;49(4):513–518. doi: 10.1111/imj.14064Pouillon L, Ferrante M, Van Assche G, et al. Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab. Clin Gastroenterol Hepatol. 2018;16(8):1276–1283.e1. doi: 10.1016/j.cgh.2017.11.046Pouillon L, Ferrante M, Van Assche G, et al. Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab. Clin Gastroenterol Hepatol. 2018;16(8):1276–1283.e1. doi: 10.1016/j.cgh.2017.11.046Strik AS, Löwenberg M, Mould DR, et al. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scand J Gastroenterol. 2021;56(2):145–154. doi: 10.1080/00365521.2020.1856405Strik AS, Löwenberg M, Mould DR, et al. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scand J Gastroenterol. 2021;56(2):145–154. doi: 10.1080/00365521.2020.1856405Kamperidis N, Middleton P, et al. Impact of therapeutic drug level monitoring on outcomes of patients with Crohn’s disease treated with Infliximab: real world data from a retrospective single centre cohort study. Frontline Gastroenterol. 2019 Oct;10(4):330–336. doi: 10.1136/flgastro-2018-101024Kamperidis N, Middleton P, et al. Impact of therapeutic drug level monitoring on outcomes of patients with Crohn’s disease treated with Infliximab: real world data from a retrospective single centre cohort study. Frontline Gastroenterol. 2019 Oct;10(4):330–336. doi: 10.1136/flgastro-2018-101024Sánchez-Hernández JG, Rebollo N, Martin-Suarez A, et al. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoringprogramme of infliximab treatments in inflammatory bowel disease. Br J Clin Pharmacol. 2020;86(6):1165–1175. doi: 10.1111/bcp.14229Sánchez-Hernández JG, Rebollo N, Martin-Suarez A, et al. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoringprogramme of infliximab treatments in inflammatory bowel disease. Br J Clin Pharmacol. 2020;86(6):1165–1175. doi: 10.1111/bcp.14229Papamichael K, Cheifetz AS. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Curr Opin Rheumatol. 2020;32(4):371–379. doi: 10.1097/BOR.0000000000000713Papamichael K, Cheifetz AS. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Curr Opin Rheumatol. 2020;32(4):371–379. doi: 10.1097/BOR.0000000000000713Педа Е.С., Александров Т.Л., Баранова Т.А., и соавт. Эффективность и безопасность перехода с терапии оригинальными препаратами на биосимиляры при лечении воспалительных заболеваний кишечника. Экспериментальная и клиническая гастроэнтерология. 2021;195(11):35–41. doi: 10.31146/1682-8658-ecg195-11-35-41Peda E.S., Alexandrov T.L., Baranova T.A., et al. The effectiveness and safety of switching from therapy with original drugs to biosimilars in the treatment of inflammatory bowel diseases. Experimental and clinical gastroenterology. 2021;195(11):35–41 (in Russ.). doi: 10.31146/1682-8658-ecg195-11-35-41Князев О.В., Звяглова М.Ю., Каграманова А.В., и соавт. Потеря ответа и частота нежелательных явлений у пациентов с язвенным колитом и болезнью Крона при переходе с оригинального препарата инфликсимаб на его биосимиляры. Терапевтический архив. 2021;93(2):150–157. doi: 10.26442/00403660.2021.02.200624Knyazev O.V., Zvyaglova M.Yu., Kagramanova A.V., et al. Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original drug infliximab to its biosimilars. Therapeutic Archive. 2021;93(2):150–157. (in Russ.). doi: 10.26442/00403660.2021.02.200624Hanzel J, Jansen JM, TerSteege RWF, et al. Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study. Inflamm Bowel Dis. 2022;28(4):495–501. doi: 10.1093/ibd/izab099Hanzel J, Jansen JM, TerSteege RWF, et al. Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study. Inflamm Bowel Dis. 2022;28(4):495–501. doi: 10.1093/ibd/izab099Cohen HP, Blauvelt A, Rifkin RM, et al. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of ClinicalCohen HP, Blauvelt A, Rifkin RM, et al. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of ClinicalOutcomes. Drugs. 2018;78(4):463–478. doi: 10.1007/s40265-018-0881-yOutcomes. Drugs. 2018;78(4):463–478. doi: 10.1007/s40265-018-0881-yYe BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393(10182):1699–1707. doi: 10.1016/S0140-6736(18)32196-2Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393(10182):1699–1707. doi: 10.1016/S0140-6736(18)32196-2Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, et al. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Lancet Gastroenterol Hepatol. 2018;3(6):404–412. doi: 10.1016/S2468-1253(18)30082-7Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, et al. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Lancet Gastroenterol Hepatol. 2018;3(6):404–412. doi: 10.1016/S2468-1253(18)30082-7Narula N, Marshall JK, Colombel JF, et al. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. Am J Gastroenterol. 2016;111(4):477–91. doi: 10.1038/ajg.2016.7Narula N, Marshall JK, Colombel JF, et al. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. Am J Gastroenterol. 2016;111(4):477–91. doi: 10.1038/ajg.2016.7Подольская Д.В., Шапина М.В., Баранова Т.А., и соавт. Эффективность тофацитиниба в качестве «терапии спасения» у пациентов с язвенным колитом тяжелой степени. Колопроктология. 2021;20(3):43–50. doi: 10.33878/2073-7556-2021-20-3-43-50Podolskaya D.V., Shapina M.V., Baranova T.A., et al. The effectiveness of tofacitinib as a “rescue therapy” in patients with severe ulcerative colitis. Koloproktologia. 2021;20(3):43–50 (in Russ.). doi: 10.33878/2073-7556-2021-20-3-43-50Singh S, Murad MH, Fumery M, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(12):1002–1014. doi: 10.1016/S2468-1253(21)00312-5Singh S, Murad MH, Fumery M, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(12):1002–1014. doi: 10.1016/S2468-1253(21)00312-5Singh S, Proctor D, Scott FI, et al. AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease. Gastroenterology. 2021;160(7):2512–2556.e9. doi: 10.1053/j.gastro.2021.04.023Singh S, Proctor D, Scott FI, et al. AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease. Gastroenterology. 2021;160(7):2512–2556.e9. doi: 10.1053/j.gastro.2021.04.023Singh S, Fumery M, Sandborn WJ, et al. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther. 2018;48(4):394–409. doi: 10.1111/apt.14852Singh S, Fumery M, Sandborn WJ, et al. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther. 2018;48(4):394–409. doi: 10.1111/apt.14852Vuyyuru SK, Kante B, Kumar P, et al. Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease. Sci Rep. 2021;11(1):11704. doi: 10.1038/s41598-021-90660-2Vuyyuru SK, Kante B, Kumar P, et al. Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease. Sci Rep. 2021;11(1):11704. doi: 10.1038/s41598-021-90660-2Lu C, Baraty B, Lee Robertson H, et al. Systematic review: medical therapy for fibrostenosing Crohn’s disease. Aliment Pharmacol Ther. 2020;51(12):1233–1246. doi: 10.1111/apt.15750Lu C, Baraty B, Lee Robertson H, et al. Systematic review: medical therapy for fibrostenosing Crohn’s disease. Aliment Pharmacol Ther. 2020;51(12):1233–1246. doi: 10.1111/apt.15750Hashash JG, Mourad FH. Positioning biologics in the management of moderate to severe Crohn’s disease. Curr Opin Gastroenterol. 2021;37(4):351–356. doi: 10.1097/MOG.0000000000000735Hashash JG, Mourad FH. Positioning biologics in the management of moderate to severe Crohn’s disease. Curr Opin Gastroenterol. 2021;37(4):351–356. doi: 10.1097/MOG.0000000000000735Bouguen G, Huguet A, Amiot A, et al. Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn’s Disease. Clin Gastroenterol Hepatol. 2020;18(3):628–636. doi: 10.1016/j.cgh.2019.05.027Bouguen G, Huguet A, Amiot A, et al. Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn’s Disease. Clin Gastroenterol Hepatol. 2020;18(3):628–636. doi: 10.1016/j.cgh.2019.05.027Lee MJ, Parker CE, Taylor SR, et al. Efficacy of Medical Therapies for Fistulizing Crohn’s Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16(12):1879–1892. doi: 10.1016/j.cgh.2018.01.030Lee MJ, Parker CE, Taylor SR, et al. Efficacy of Medical Therapies for Fistulizing Crohn’s Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16(12):1879–1892. doi: 10.1016/j.cgh.2018.01.030Strik AS, Löwenberg M, Buskens CJ, et al. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn’s disease patients. Scand J Gastroenterol. 2019;54(4):453–458. doi: 10.1080/00365521.2019.1600014Strik AS, Löwenberg M, Buskens CJ, et al. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn’s disease patients. Scand J Gastroenterol. 2019;54(4):453–458. doi: 10.1080/00365521.2019.1600014Tandon P, Rhee GG, Schwartz D, et al. Strategies to Optimize Anti-tumor Necrosis Factor Therapy for Perianal Fistulizing Crohn’s Disease: A Systematic Review. Dig Dis Sci. 2019;64(11):3066–3077. doi: 10.1007/s10620-019-05635-1Tandon P, Rhee GG, Schwartz D, et al. Strategies to Optimize Anti-tumor Necrosis Factor Therapy for Perianal Fistulizing Crohn’s Disease: A Systematic Review. Dig Dis Sci. 2019;64(11):3066–3077. doi: 10.1007/s10620-019-05635-1Plevris N, Jenkinson PW, Arnott ID, et al. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn’s disease. Eur J Gastroenterol Hepatol. 2020;32(1):32–37. doi: 10.1097/MEG.0000000000001561Plevris N, Jenkinson PW, Arnott ID, et al. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn’s disease. Eur J Gastroenterol Hepatol. 2020;32(1):32–37. doi: 10.1097/MEG.0000000000001561Lewis JD, Scott FI, Brensinger CM, et al. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. Am J Gastroenterol. 2018;113(3):405–417. doi: 10.1038/ajg.2017.479Lewis JD, Scott FI, Brensinger CM, et al. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. Am J Gastroenterol. 2018;113(3):405–417. doi: 10.1038/ajg.2017.479Nencini F, Vultaggio A, Pratesi S, et al. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. J Allergy Clin Immunol Pract. 2018;6(6):2065–2072.e2. doi: 10.1016/j.jaip.2018.04.007Nencini F, Vultaggio A, Pratesi S, et al. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. J Allergy Clin Immunol Pract. 2018;6(6):2065–2072.e2. doi: 10.1016/j.jaip.2018.04.007Fumery M, Tilmant M, Yzet C, et al. Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis. Dig Liver Dis. 2019;51(4):484–488. doi: 10.1016/j.dld.2018.12.002Fumery M, Tilmant M, Yzet C, et al. Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis. Dig Liver Dis. 2019;51(4):484–488. doi: 10.1016/j.dld.2018.12.002Kirchgesner J, Lemaitre M, Carrat F, et al. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2018;155(2):337–346.e10. doi: 10.1053/j.gastro.2018.04.012Kirchgesner J, Lemaitre M, Carrat F, et al. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2018;155(2):337–346.e10. doi: 10.1053/j.gastro.2018.04.012Singh S, Facciorusso A, Dulai PS, et al. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020;18(1):69–81.e3. doi: 10.1016/j.cgh.2019.02.044Singh S, Facciorusso A, Dulai PS, et al. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020;18(1):69–81.e3. doi: 10.1016/j.cgh.2019.02.044Khan N, Patel D, Trivedi C, et al. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2018;16(12):1919–1927.e3. doi: 10.1016/j.cgh.2017.12.052Khan N, Patel D, Trivedi C, et al. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2018;16(12):1919–1927.e3. doi: 10.1016/j.cgh.2017.12.052Holmer A, Singh S. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases. Expert Rev Clin Immunol. 2019;15(9):969–979. doi: 10.1080/1744666X.2019.1646127Holmer A, Singh S. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases. Expert Rev Clin Immunol. 2019;15(9):969–979. doi: 10.1080/1744666X.2019.1646127Lukin D, Weiss A, Aniwan S, et al. Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis. Journal of Crohn’s and Colitis. 12(supplement_1), S036–S036. doi: 10.1093/ecco-jcc/jjx180.046Lukin D, Weiss A, Aniwan S, et al. Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis. Journal of Crohn’s and Colitis. 12(supplement_1), S036–S036. doi: 10.1093/ecco-jcc/jjx180.046Bohm M, Xu R, Zhang Y, et al. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn’s disease. Aliment Pharmacol Ther. 2020;52(4):669–681. doi: 10.1111/apt.15921Bohm M, Xu R, Zhang Y, et al. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn’s disease. Aliment Pharmacol Ther. 2020;52(4):669–681. doi: 10.1111/apt.15921Kedia S, Mouli VP, Kamat N, et al. Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2020;115(3):340–349. doi: 10.14309/ajg.0000000000000527Kedia S, Mouli VP, Kamat N, et al. Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2020;115(3):340–349. doi: 10.14309/ajg.0000000000000527Muller M, D’Amico F, Bonovas S, et al. TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. J Crohns Colitis. 2021;15(5):840–859. doi: 10.1093/ecco-jcc/jjaa186Muller M, D’Amico F, Bonovas S, et al. TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. J Crohns Colitis. 2021;15(5):840–859. doi: 10.1093/ecco-jcc/jjaa186Lichtenstein GR, Feagan BG, Cohen RD, et al. Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018;24(3):490–501. doi: 10.1093/ibd/izx072Lichtenstein GR, Feagan BG, Cohen RD, et al. Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018;24(3):490–501. doi: 10.1093/ibd/izx072Waljee AK, Higgins PDR, Jensen CB, et al. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. Lancet Gastroenterol Hepatol. 2020;5(3):276–284. doi: 10.1016/S2468-1253(19)30362-0Waljee AK, Higgins PDR, Jensen CB, et al. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. Lancet Gastroenterol Hepatol. 2020;5(3):276–284. doi: 10.1016/S2468-1253(19)30362-0Micic D, Komaki Y, Alavanja A, et al. Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Gastroenterol. 2019;53(1):e1–e11. doi: 10.1097/MCG.0000000000000865Micic D, Komaki Y, Alavanja A, et al. Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Gastroenterol. 2019;53(1):e1–e11. doi: 10.1097/MCG.0000000000000865Chupin A, Perduca V, Meyer A, et al. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1289–1297. doi: 10.1111/apt.16050Chupin A, Perduca V, Meyer A, et al. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1289–1297. doi: 10.1111/apt.16050Levhar N, Ungar B, Kopylov U, et al. Propagation of EBVdriven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020;26(9):1330–1339. doi: 10.1093/ibd/izaa065Levhar N, Ungar B, Kopylov U, et al. Propagation of EBVdriven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020;26(9):1330–1339. doi: 10.1093/ibd/izaa065Holmer A, Singh S. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases. Expert Rev Clin Immunol. 2019;15(9):969–979. doi: 10.1080/1744666X.2019.1646127Holmer A, Singh S. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases. Expert Rev Clin Immunol. 2019;15(9):969–979. doi: 10.1080/1744666X.2019.1646127Weizman AV, Sharma R, Afzal NM, et al. Stricturing and Fistulizing Crohn’s Disease Is Associated with Anti-tumor Necrosis FactorInduced Psoriasis in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(9):2430–2438. doi: 10.1007/s10620-018-5096-2Weizman AV, Sharma R, Afzal NM, et al. Stricturing and Fistulizing Crohn’s Disease Is Associated with Anti-tumor Necrosis FactorInduced Psoriasis in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(9):2430–2438. doi: 10.1007/s10620-018-5096-2

The authors declare that there are no conflicts of interest present.